Patents Examined by Maher M. Haddad
  • Anti-PD-1 monoclonal antibody, and preparation method therefor and application thereof
    Patent number: 11254746
    Abstract: An anti-human PD-1 monoclonal antibody, and a preparation method therefor and an application thereof. The anti-human PD-1 monoclonal antibody has good bioactivity, can effectively bind with an extracellular region of a human PD-1 protein receptor, and can effectively seal PD-1 protein at protein level and cellular level and block the binding of the PD-1 protein with a ligand PD-L1, thereby effectively enhancing immunity. The monoclonal antibody can be applied independently or jointly with other antitumor drugs to tumor immunotherapy and the diagnosis and screening of patients with PD-L1 positive tumors; and the monoclonal antibody has a promising prospect in the preparation of drugs for treating tumors, resisting autoimmune diseases and the like.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: February 22, 2022
    Assignee: SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LT
    Inventors: Jie Zhao, Honghai Gao, Jinlin Guo, Wei Dang, Lingqiao Zhu, Chenghai Zhang, Le Zhao, Jianhe Chen, Haomin Huang, Zhenping Zhu
  • Administration of agents for the treatment of inflammation
    Patent number: 11248051
    Abstract: A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: February 15, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Julie Taylor, Theodore A. Yednock
  • Mesenchymal stem cell differentiation
    Patent number: 11241482
    Abstract: The present invention provides for methods and compositions for treating or preventing arthritis and joint injury.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: February 8, 2022
    Assignees: NOVARTIS AG, The Scripps Research Institute
    Inventors: Lori Jennings, Kristen Johnson, Peter Schultz
  • Anti-PD-L1 antibodies and uses thereof
    Patent number: 11220546
    Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 116, a VH CDR3 of SEQ ID NO: 117, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: January 11, 2022
    Assignee: I-Mab Biopharma US Limited
    Inventors: Lei Fang, Yongqiang Wang, Zhengyi Wang, Bingshi Guo, Jingwu Zang
  • Engineered antibody for inhibition of fibrosis
    Patent number: 11208472
    Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: December 28, 2021
    Assignee: Thomas Jefferson University
    Inventors: Andrzej Fertala, Andrzej Steplewski
  • Anti-TM4SF1 antibodies and methods of using same
    Patent number: 11208495
    Abstract: Anti-TM4SF1 antibodies, and antigen-binding fragments thereof, are described that bind to an epitope on the ECL2 loop of human TM4SF1. Methods of use of said antibodies and fragments are also described, including for the inhibition of metastasis.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: December 28, 2021
    Assignee: ANGIEX, INC.
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Harold F. Dvorak, Leonard G. Presta
  • Serum albumin-binding fibronectin type III domains
    Patent number: 11203630
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: December 21, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan H. Davis, David Fabrizio
  • Fusion proteins for inhibiting angiogenesis
    Patent number: 11192927
    Abstract: The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: December 7, 2021
    Assignee: Allgenesis Biotherapeutics Inc.
    Inventors: Pei-Tzu Wu, Jia-Hau Shiu, Madhu Cherukury, Tan Nguyen, Kevin Zen
  • Protein binding to fibronectin B domain
    Patent number: 11192943
    Abstract: The present invention relates to an epitope on fibronectin B (ED-B) domain, more specifically to an antibody or an antibody fragment of ED-B domain, and can be widely applied in in-vitro detection and in-vivo positioning of ED-B domain as well as in targeted cancer therapy.
    Type: Grant
    Filed: September 29, 2018
    Date of Patent: December 7, 2021
    Assignee: HEFEI LIFEON PHARMACEUTICAL CO., LTD.
    Inventors: Mei Zhang, Junqiu Ji, Meihua Gao, Jun Chen
  • Methods and compositions for improving antiangiogenic therapy with anti-integrins
    Patent number: 11185585
    Abstract: Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an antiangiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: November 30, 2021
    Assignee: The Regents of the University of California
    Inventors: Warren Shawn Carbonell, Manish Kumar Aghi
  • Anti-ANG2 antibody
    Patent number: 11174309
    Abstract: An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor and Ang2, and related methods and compositions.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: November 16, 2021
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Kyung Eun Kim, Seung Ja Oh, Hyo Seon Lee, Sang Yeul Han
  • Use of anti-FAM19A5 antibodies for treating fibrosis
    Patent number: 11155613
    Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: October 26, 2021
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Jae-Keun Lee, Dong Sik Kim
  • Variant antibodies that bind OX40
    Patent number: 11142579
    Abstract: The present disclosure provides variant anti-OX40 antibodies that mimic the activity of OX40L by behaving as an agonist against receptor OX40 to enhance T cell clonal expansion and differentiation. The variant anti-OX40 antibodies exhibit improved binding affinity for OX40 and improved agnostic activity, compared to a wild type anti-OX40 antibody (wild type 2B4 clone) from which the variant clones are derived. The variant anti-OX40 antibodies specifically bind OX40 receptors on activated T lymphocytes, stimulate proliferation of effector T cells, stimulate proliferation of effector T cells in the presence of regulatory T cells, and stimulate production of at least one cytokine from effector T cells.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: October 12, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventor: Min Soo Kim
  • Anti-integrin ?1 antibody compositions and methods of use thereof
    Patent number: 11142576
    Abstract: The current invention provides human variable chain framework regions and humanized antibodies comprising the framework regions, the antibodies being specific for integrin ?1. The invention also provides methods for utilizing the antibodies, for example to treat diseases such as cancer.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: October 12, 2021
    Assignee: Oncosynergy, Inc.
    Inventor: W. Shawn Carbonell
  • Antibodies to symmetrically dimethylated arginine analytes and use thereof
    Patent number: 11136412
    Abstract: Disclosed is an antibody which binds to a symmetrically dimethylated arginine analyte that can be used to detect a symmetrically dimethylated arginine analyte in a sample, such as in a homogeneous enzyme immunoassay method.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: October 5, 2021
    Assignee: ARK Diagnostics, Inc.
    Inventors: Johnny Valdez, Byung Sook Moon, Ki Chung, Yunfei Chen
  • Antibody to fibrosis-related molecule and medical application thereof
    Patent number: 11117962
    Abstract: The present invention provides an antibody to a fibrosis-related molecule and medical application thereof. The antibody of the present invention is an antibody that binds to CHL1 protein and an antibody that neutralizes the binding of the CHL1 protein to a fibroblast.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: September 14, 2021
    Assignee: The University of Tokyo
    Inventors: Yosuke Kurashima, Hiroshi Kiyono
  • Anti-EMAP II antibody and use thereof
    Patent number: 11104728
    Abstract: The present invention relates to an anti-EMAP II antibody or an antigen-binding fragment thereof, a nucleic acid molecule for coding the same, or a preparation method thereof. Also, the present invention provides a method for using the anti-EMAP II antibody or the antigen-binding fragment thereof in preventing, treating or diagnosing EMAP II-mediated diseases, for example, TNF-?-mediated disease or Alzheimer's disease. Furthermore, the present invention provides a method for using the anti-EMAP II antibody or the antigen-binding fragment thereof in detecting or quantifying an EMAP II antigen. The antibody of the present invention may exhibit a more improved antigen-binding capacity compared to existing anti-EMAP antibodies and may treat the TNF-?-mediated disease more effectively.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: August 31, 2021
    Assignee: HUB Biotech Co., Ltd.
    Inventors: Sang Gyu Park, Gook-Jin Kang
  • Chimeric antigen receptors comprising BCMA-specific fibronectin type III domains and uses thereof
    Patent number: 11096998
    Abstract: BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: August 24, 2021
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Chen Ni Chin, John Lee, Timothy McCabe, Jill Mooney, Michael Naso, William Strohl
  • Anti-OX40 antibodies and uses thereof
    Patent number: 11091558
    Abstract: An isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human OX40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-OX40 antibody of the invention.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: August 17, 2021
    Assignee: BEIJING MABWORKS BIOTECH CO. LTD.
    Inventors: Wenqi Hu, Jiangmei Li, Lun Jiang, Feng Li
  • Methods for diagnosing and treating inflammatory bowel disease
    Patent number: 11091551
    Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: August 17, 2021
    Assignee: Genentech, Inc.
    Inventors: Mary Keir, Gaik Wei Tew